Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

Core Insights - Sight Sciences, Inc. announced the twelve-month results from the SAHARA trial, demonstrating the effectiveness of TearCare in treating dry eye disease (DED) compared to Restasis [1][3][11] Study Results - Patients previously treated with Restasis showed clinically meaningful improvements in DED symptoms after switching to TearCare, with benefits lasting for six months post-treatment [2][6] - Phase 2 of the SAHARA trial confirmed that TearCare is effective regardless of prior Restasis treatment, indicating its potential as both a primary and secondary treatment option for DED [3][4] - The trial included 345 subjects in Phase 1 and 163 patients crossed over to TearCare in Phase 2, with significant improvements in tear break-up time (TBUT) and other dry eye measures [4][5] Statistical Findings - TBUT improved by 1.1 seconds at three months and 0.6 seconds at twelve months after switching to TearCare, both statistically significant (p<.001) [8] - Other measures, including meibomian gland secretion score (MGSS) and ocular surface disease index (OSDI), also showed significant improvements post-treatment [8][10] - The study reported that mean values for TBUT, MGSS, and other ocular signs improved significantly compared to baseline measurements [10][11] Future Directions - The SAHARA trial will continue into Phase 3, which aims to provide long-term data on the durability and effectiveness of TearCare over a two-year period [11]